21 Invest, a European investment group that invests in mid-market companies in Italy, France and Spain, founded by Alessandro Benetton, announces the acquisition of Radius through Else Solutions, an Italian company operating in the distribution and manufacturing of products for the medical sector, which has been part of the 21 Invest Healthcare portfolio since October 2025.

Radius, founded by Mauro Mei, a long-standing entrepreneur and executive in the industry, is headquartered in Budrio (Bologna). The company distributes highly innovative, technologically advanced products and serves as a benchmark for the Italian scientific community in the fields of radiotherapy, nuclear medicine, and pre-clinical research, offering products from leading international suppliers.

The company is currently managed by Mauro Mei and Ludovica Mei, who will remain involved in its management following the integration with Else Solutions. The Mei family will also reinvest in the transaction, confirming its commitment to the company’s growth project.

In recent years, Radius has demonstrated a strong growth trajectory, generating approximately €17 million in revenue in 2025, with an average annual growth rate of 40% over the past three years, and an EBITDA of approximately €3.2 million, up 60% compared to 2024.

The acquisition is part of a broader development strategy for Else Solutions, aimed at consolidating its leadership in distribution and expanding its presence in the radiopharmaceutical handling systems sector, where the company stands out through a highly competitive and cutting-edge product portfolio, supported by enhanced manufacturing capabilities. At the same time, Else Solutions will continue its international expansion into high-potential markets, a process already launched during 2025.

Following the acquisition, the group will reach aggregate revenues of €35 million, EBITDA of approximately €7 million, and a workforce of around 70 employees, consolidating its growth trajectory and doubling its size in less than one year.

Alessandro Damiano, Partner at 21 Invest, comments: "We are pleased to have supported Else Solutions in this transaction, with the addition of a cutting-edge player in the radiotherapy and nuclear medicine sector. Less than a year after the 21 Invest Healthcare fund's investment in Else Solutions, this transaction allows us to consolidate our position as a sector leader, doubling in size and contributing to improving the quality of patient care, in line with our growth and value-creation strategy."

Emiliano Spagnolo, CEO of Else Solutions: "We are very pleased with this transaction and to be able to collaborate with Mauro and Ludovica Mei. Thanks to this acquisition, Else will reach a size that will see us recognized as one of the leading players in the supply of highly qualified medical solutions in high-growth-potential niche sectors. Radius will allow us to create revenue synergies across our respective customer bases, also making it possible to reach the largest possible number of users and thus broaden our therapeutic offering across the national territory and begin our expansion abroad".

Mauro Mei, founder and CEO of Radius: "From the very beginning, we considered Else Solutions our preferred partner for the development of Radius. Moreover, with great enthusiasm, we joined Else Solutions' development project with our own investment, to which we will be able to make a significant contribution".